Cybin Inc
CYBN7.532USD
-0.028-0.37%
Market hours （ET）Quotes delayed by 15 min
162.77MMarket Cap
LossP/E TTM
More Details of Cybin Inc Company
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
Company Info
Ticker SymbolCYBN
Company nameCybin Inc
IPO dateJan 05, 2018
CEOMr. Douglas (Doug) Drysdale
Number of employees50
Security typeOrdinary Share
Fiscal year-endJan 05
Address100 King Street West
CityTORONTO
Stock exchangeAequitas NEO-L
CountryCanada
Postal codeM5X 1C9
Phone19087648385
Websitehttps://www.cybin.com
Ticker SymbolCYBN
IPO dateJan 05, 2018
CEOMr. Douglas (Doug) Drysdale
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Alex Nivorozhkin
Mr. Alex Nivorozhkin
Chief Scientific Officer
Chief Scientific Officer
5.25M
+5.65%
Mr. George Tziras
Mr. George Tziras
Director, Chief Business Officer
Director, Chief Business Officer
1.29M
--
Mr. Eric How-Lun So
Mr. Eric How-Lun So
Executive Chairman of the Board, President
Executive Chairman of the Board, President
311.12K
-97.37%
Mr. Paul Glavine
Mr. Paul Glavine
Director, Chief Growth Officer
Director, Chief Growth Officer
299.67K
-97.37%
Mr. Gabriel Fahel
Mr. Gabriel Fahel
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
287.70K
+0.24%
Ms. Theresa Firestone
Ms. Theresa Firestone
Lead Independent Director
Lead Independent Director
1.06K
-97.37%
Mr. Grant B. Froese
Mr. Grant B. Froese
Independent Director
Independent Director
--
--
Mr. Greg Cavers
Mr. Greg Cavers
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Mark Lawson
Mr. Mark Lawson
Independent Director
Independent Director
--
--
Mr. Douglas (Doug) Drysdale
Mr. Douglas (Doug) Drysdale
Chief Executive Officer
Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Alex Nivorozhkin
Mr. Alex Nivorozhkin
Chief Scientific Officer
Chief Scientific Officer
5.25M
+5.65%
Mr. George Tziras
Mr. George Tziras
Director, Chief Business Officer
Director, Chief Business Officer
1.29M
--
Mr. Eric How-Lun So
Mr. Eric How-Lun So
Executive Chairman of the Board, President
Executive Chairman of the Board, President
311.12K
-97.37%
Mr. Paul Glavine
Mr. Paul Glavine
Director, Chief Growth Officer
Director, Chief Growth Officer
299.67K
-97.37%
Mr. Gabriel Fahel
Mr. Gabriel Fahel
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
287.70K
+0.24%
Ms. Theresa Firestone
Ms. Theresa Firestone
Lead Independent Director
Lead Independent Director
1.06K
-97.37%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 30
Updated: Wed, Jul 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rands (Peter David)
72.07%
Nivorozhkin (Alex)
22.81%
Tang Capital Management, LLC
7.95%
Deep Track Capital LP
6.65%
Global X Investments Canada Inc.
5.82%
Shareholders
Shareholders
Proportion
Rands (Peter David)
72.07%
Nivorozhkin (Alex)
22.81%
Tang Capital Management, LLC
7.95%
Deep Track Capital LP
6.65%
Global X Investments Canada Inc.
5.82%
Shareholder Types
Shareholders
Proportion
Individual Investor
109.49%
Hedge Fund
28.45%
Investment Advisor
6.51%
Investment Advisor/Hedge Fund
6.43%
Private Equity
0.49%
Research Firm
0.47%
Bank and Trust
0.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
202
58.02M
152.31%
-77.17M
2025Q1
209
57.54M
286.29%
-78.15M
2024Q4
205
59.72M
283.54%
-81.34M
2024Q3
197
62.29M
285.74%
-324.75M
2024Q2
204
344.93M
166.65%
-48.46M
2024Q1
195
368.84M
163.99%
+249.67M
2023Q4
177
108.66M
110.45%
+25.70M
2023Q3
166
58.71M
23.51%
+14.44M
2023Q2
156
50.00M
26.24%
+942.60K
2023Q1
152
52.80M
27.84%
+4.58M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rands (Peter David)
16.59M
76.78%
-3.01M
-15.34%
Nov 14, 2023
Nivorozhkin (Alex)
5.25M
24.3%
+280.74K
+5.65%
Mar 31, 2024
Tang Capital Management, LLC
1.83M
8.47%
+500.00K
+37.59%
Mar 31, 2025
Deep Track Capital LP
1.53M
7.08%
--
--
Mar 31, 2025
Global X Investments Canada Inc.
1.34M
6.2%
-213.08K
-13.73%
Feb 29, 2024
Point72 Asset Management, L.P.
1.33M
6.14%
+508.22K
+62.13%
May 20, 2025
Tziras (George)
1.29M
5.99%
--
--
Jul 24, 2024
Bartlone (Aaron Frank)
901.07K
4.17%
+200.00K
+28.53%
Jun 28, 2024
Rosalind Advisors, Inc.
810.92K
3.75%
--
--
Mar 31, 2025
Acorn Capital Advisors, LLC
734.39K
3.4%
+1.00
+0.00%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
AdvisorShares Psychedelics ETF
7.05%
iShares Biotechnology ETF
0.02%
Simplify Propel Opportunities ETF
0%
AdvisorShares Psychedelics ETF
Proportion7.05%
iShares Biotechnology ETF
Proportion0.02%
Simplify Propel Opportunities ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 28, 2024
Merger
38<1
Aug 28, 2024
Merger
38<1
Aug 28, 2024
Merger
38<1
Aug 28, 2024
Merger
38<1
Date
Type
Ratio
Aug 28, 2024
Merger
38<1
Aug 28, 2024
Merger
38<1
Aug 28, 2024
Merger
38<1
Aug 28, 2024
Merger
38<1
